Literature DB >> 19728024

Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.

Matjaz Sever1, Hagop Kantarjian1, Sherry Pierce1, Nitin Jain1, Zeev Estrov1, Jorge Cortes1, Srdan Verstovsek2.   

Abstract

Cytogenetic abnormalities in patients with essential thrombocythemia (ET) are infrequent. Their role in survival of patients and disease transformation is not extensively studied. We describe cytogenetic abnormalities in 172 patients with ET at a single institution. At presentation nine (5.2%) patients had cytogenetic abnormality and three (1.7%) additional patients acquired them during follow-up. Survival of patients with cytogenetic changes at presentation did not differ when compared to the patients with normal karyotype. The more common were abnormalities of chromosome 9 (n = 4), 20 (n = 2), 5 (n = 2), and complex abnormalities (n = 2). Forty-one patients (23.8%) had additional cytogenetic tests performed for monitoring purposes during follow-up. Five patients (2.9%) with normal karyotype transformed to myelofibrosis (MF) without developing new cytogenetic changes at transformation. Two patients (1.2%) with normal karyotypes at presentation transformed to myelodysplastic syndrome and acute myeloid leukemia, respectively. Both acquired complex cytogenetic changes at the time of transformation. There is no rationale for repeating cytogenetic tests in ET patients on follow up, unless blood cell count changes suggest possible transformation.

Entities:  

Mesh:

Year:  2009        PMID: 19728024      PMCID: PMC4209590          DOI: 10.1007/s12185-009-0411-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  28 in total

1.  Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study.

Authors:  M Sessarego; R Defferrari; A M Dejana; A M Rebuttato; G Fugazza; E Salvidio; F Ajmar
Journal:  Cancer Genet Cytogenet       Date:  1989-11

2.  5q--in essential thrombocythemia.

Authors:  J Welborn
Journal:  Cancer Genet Cytogenet       Date:  1993-06

Review 3.  5q-syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders?

Authors:  T Koike; Y Uesugi; K Toba; M Narita; I Fuse; M Takahashi; A Shibata
Journal:  Leukemia       Date:  1995-03       Impact factor: 11.528

4.  Deletion of the long arm of chromosome 5 in essential thrombocythemia.

Authors:  M D Reis; G D Sher; A Lakhani; I D Dubé; J S Senn; P H Pinkerton
Journal:  Cancer Genet Cytogenet       Date:  1992-07-01

5.  5q- syndrome presenting chronic myeloproliferative disorders-like manifestation: a case report.

Authors:  H Takahashi; T Furukawa; S Hashimoto; N Kanazawa; N Satoh; N Suzuki; J Takizawa; Y Uesugi; M Takahashi; Y Aizawa; T Koike
Journal:  Am J Hematol       Date:  2000-06       Impact factor: 10.047

6.  Acquired inv(9): what is its significance?

Authors:  Jaime L Betz; Ahmed S Behairy; Pedro Rabionet; Budi Tirtorahardjo; Mathew W Moore; Philip D Cotter
Journal:  Cancer Genet Cytogenet       Date:  2005-07-01

7.  Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.

Authors:  Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Claudia Schoch
Journal:  Ann Hematol       Date:  2005-02-04       Impact factor: 3.673

Review 8.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

9.  Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.

Authors:  Naseema Gangat; Ayalew Tefferi; Gita Thanarajasingam; Mrinal Patnaik; Susan Schwager; Rhett Ketterling; Alexandra P Wolanskyj
Journal:  Eur J Haematol       Date:  2009-02-19       Impact factor: 2.997

Review 10.  Cytogenetic and molecular genetic aspects of essential thrombocythemia.

Authors:  David P Steensma; Ayalew Tefferi
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

View more
  3 in total

1.  Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.

Authors:  Vincent T Ma; Philip S Boonstra; Kamal Menghrajani; Cecelia Perkins; Krisstina L Gowin; Ruben A Mesa; Jason R Gotlib; Moshe Talpaz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-03-02

2.  Significance of cytogenetic abnormalities in patients with polycythemia vera.

Authors:  Matjaz Sever; Alfonso Quintás-Cardama; Sherry Pierce; Lingsha Zhou; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-04-17

3.  Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.

Authors:  Naseema Gangat; Yamna Jadoon; Natasha Szuber; Curtis A Hanson; Alexandra P Wolanskyj-Spinner; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2022-03-17       Impact factor: 11.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.